Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Phase 1 Completed
26 enrolled 24 charts
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Phase 1 Completed
37 enrolled
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Phase 1 Withdrawn
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
Phase 1 Terminated
6 enrolled
Depsipeptide to Treat Thyroid and Other Advanced Cancers
Phase 1 Completed
28 enrolled
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Phase 1 Completed
26 enrolled
Depsipeptide in Treating Patients With Solid Tumors
Phase 1 Completed
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
Phase 1 Completed
36 enrolled
FR901228 in Treating Patients With Hematologic Cancer
Phase 1 Completed
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
Phase 1 Completed
30 enrolled